Core Insights - Atossa Therapeutics, Inc. has announced that its Founder and CEO, Dr. Steven Quay, has been recognized as one of "The Top 50 Healthcare Technology CEOs of 2025" for his leadership in advancing innovative biotechnology solutions [1][2][3] Company Overview - Atossa Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies in oncology and other areas of significant unmet clinical need [4] - The company's lead product candidate, (Z)-endoxifen, is a precision-engineered endocrine therapy currently undergoing multiple Phase 2 clinical trials [2][4] - Atossa's strategy emphasizes disciplined capital allocation, focusing on programs that can enable future regulatory submissions and potential commercialization [4] Product Development - (Z)-endoxifen has been optimized as a potent selective estrogen receptor modulator/degrader (SERM/D) with additional PKC1 inhibition, designed for consistent systemic exposure independent of CYP2D6 metabolism [2] - The company is also exploring the application of (Z)-endoxifen for Duchenne Muscular Dystrophy (DMD) [2]